Valirx (VAL)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

8.75p
   
  • Change Today:
    -0.50p
  • 52 Week High: 25.00
  • 52 Week Low: 8.51
  • Currency: UK Pounds
  • Shares Issued: 102.32m
  • Volume: 1,105,967
  • Market Cap: £8.95m
  • RiskGrade: 435

Latest ShareCast News

ValiRx incorporates new wholly-owned lab subsidiary

By Josh White

Date: Wednesday 01 Mar 2023

(Sharecast News) - Life science company ValiRx announced the incorporation of a new wholly-owned subsidiary, Inaphaea BioLabs, on Wednesday.

ValiRx forms new majority-owned breast cancer subsidiary

By Josh White

Date: Monday 24 Oct 2022

(Sharecast News) - Women's health and cancer therapeutics company ValiRx announced the formation of a new partially-owned subsidiary, Cytolytix, on Monday, which had signed an intellectual property licence agreement with King's College London (KCL).

ValiRx expecting to grant extension of exclusivity to TheoremRx

By Josh White

Date: Friday 17 Jun 2022

(Sharecast News) - Cancer therapeutics and women's health-focussed ValiRx updated the market on its proposed sub-licensing agreement with TheoremRx for 'VAL201' on Friday.

ValiRx amends longstanding licence deal with Can... 20-Dec-2021 ShareCast
ValiRx adds three new patents in first half 06-Jul-2021 ShareCast
ValiRx terminates peptide drug candidate deal 27-May-2021 ShareCast
Physiomics and ValiRx enter new collaboration deal 15-Feb-2021 ShareCast
ValiRx adds four new patents to portfolio in 2020 19-Jan-2021 ShareCast
ValiRx looks to build on portfolio of drug candi... 06-Jul-2020 ShareCast
ValiRx enters collaboration agreement for Covid-... 02-Jun-2020 ShareCast
ValiRx offloads non-core IP to DDTech 29-May-2020 ShareCast
ValiRx shores up capital position with ?1.17m fu... 04-May-2020 ShareCast
ValiRx signs VAL301 deal with Japanese firm 01-May-2020 ShareCast
ValiRx raises ?0.2m through placing with new inv... 01-Apr-2020 ShareCast
ValiRx signs letter of intent in a bid to fund V... 14-Jan-2020 ShareCast
ValiRx granted US patent for 'VAL201' compound 28-Nov-2019 ShareCast
ValiRx allowed European patent on 'VAL301' compo... 01-Aug-2019 ShareCast
ValiRx to work with Aptus on VAL301 clinical dev... 04-Jul-2019 ShareCast
ValiRx gets US patent protection for use of VAL2... 26-Jun-2019 ShareCast
ValiRx secures \'substantial amendment\' to VAL2... 20-Jun-2019 ShareCast
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Valirx Market Data

Currency UK Pounds
Share Price 8.75p
Change Today -0.50p
% Change -5.41 %
52 Week High 25.00
52 Week Low 8.51
Volume 1,105,967
Shares Issued 102.32m
Market Cap £8.95m
RiskGrade 435

Valirx Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
39.36% below the market average39.36% below the market average39.36% below the market average39.36% below the market average39.36% below the market average
16.67% below the sector average16.67% below the sector average16.67% below the sector average16.67% below the sector average16.67% below the sector average
Price Trend
77.62% below the market average77.62% below the market average77.62% below the market average77.62% below the market average77.62% below the market average
44.26% below the sector average44.26% below the sector average44.26% below the sector average44.26% below the sector average44.26% below the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 0
Buy 1
Neutral 0
Sell 0
Strong Sell 0
Total 1
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Valirx Dividends

No dividends found

Trades for 08-Jun-2023

Time Volume / Share Price
17:08 100,000 @ 8.75p
15:22 25,000 @ 8.96p
15:08 1,049 @ 8.96p
14:01 33,611 @ 8.89p
13:58 1,057 @ 8.89p

Valirx Key Personnel

CFO Gerald Desler
CEO Suzanne Dilly

Top of Page